Global Information
회사소개 | 문의 | 비교리스트

세계의 건선 치료제 시장(-2026년) : 치료 클래스별, 치료 유형별, 작용기전별, 투여 경로별, 유통경로별, 용도별, 지역별 시장 조사, 예측, COVID-19의 누적 영향

Psoriasis Drugs Market Research Report by Therapeutic Class, by Type of Treatment, by Mechanism of Action, by Route of Administration, by Distribution Channel, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

리서치사 360iResearch LLP
발행일 2021년 11월 상품 코드 1035742
페이지 정보 영문 197 Pages
가격
US $ 3,949 ₩ 4,748,000 Online Access (Single User License - 1 Year)
US $ 4,949 ₩ 5,951,000 PDF (Single User License) + Excel
US $ 5,949 ₩ 7,153,000 PDF (1-5 User License) + Excel
US $ 7,949 ₩ 9,558,000 PDF (Site License) + Excel
US $ 9,949 ₩ 11,963,000 PDF (Enterprise License) + Excel


세계의 건선 치료제 시장(-2026년) : 치료 클래스별, 치료 유형별, 작용기전별, 투여 경로별, 유통경로별, 용도별, 지역별 시장 조사, 예측, COVID-19의 누적 영향 Psoriasis Drugs Market Research Report by Therapeutic Class, by Type of Treatment, by Mechanism of Action, by Route of Administration, by Distribution Channel, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
발행일 : 2021년 11월 페이지 정보 : 영문 197 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

건선 치료제 시장 규모는 2020년에 69억 3,278만 달러, 2021년에 77억 3,283만 달러에 이르고, 연평균 성장률(CAGR) 11.87%로 성장을 지속하여 2026년까지 135억 9,520만 달러에 달할 것으로 예측됩니다.

세계의 건선 치료제(Psoriasis Drugs) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 억제요인 분석, 시장 기회, COVID-19의 영향, 치료 클래스·치료 종류·작용기전·투여 경로·유통경로·용도·지역별 시장 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

  • 조사 목적
  • 시장 세분화와 범위
  • 조사 대상년도
  • 통화와 가격
  • 언어
  • 제한 사항
  • 전제조건
  • 이해관계자

제2장 조사 방법

  • 정의 : 조사 목적
  • 결정 : 조사 디자인
  • 준비 : 조사 기기
  • 수집 : 데이터 소스
  • 분석 : 데이터 해석
  • 책정 : 데이터 검증
  • 공개 : 조사 보고서
  • 반복 : 보고서 업데이트

제3장 개요

제4장 시장 개요

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 과제
  • COVID-19의 누적 영향

제6장 치료 클래스별, 건선 치료제 시장

  • 인터류킨 억제제
  • 종양괴사인자 억제제

제7장 치료 유형별, 건선 치료제 시장

  • 생물학적 의약품
  • 소분자 전신 약물
  • 열대 요법

제8장 작용기전별, 건선 치료제 시장

  • 인터류킨 억제제
  • PDE4 억제제
  • TNF 알파 억제제

제9장 투여 경로별, 건선 치료제 시장

  • 경구
  • 비경구
  • 국소

제10장 유통 채널별, 건선 치료제 시장

  • 병원 약국
  • 온라인 약국
  • 소매 약국

제11장 용도별, 건선 치료제 시장

  • 관절염
  • 홍피성
  • 물방울양
  • 간찰부
  • 손톱
  • 판상형
  • 농포성

제12장 아메리카의 건선 치료제 시장

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제13장 아시아태평양의 건선 치료제 시장

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 싱가포르
  • 한국
  • 대만
  • 태국

제14장 유럽, 중동 및 아프리카의 건선 치료제 시장

  • 프랑스
  • 독일
  • 이탈리아
  • 네덜란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 아랍에미리트(UAE)
  • 영국

제15장 경쟁 구도

  • FPNV 포지셔닝 매트릭스
    • 상한
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석
  • 주요 기업별 시장 점유율 분석
  • 경쟁 시나리오
    • 인수합병(M&A)
    • 합의/협업/제휴
    • 신제품 발매와 강화
    • 투자/펀딩
    • 수상/표창/확대

제16장 기업 개요

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Biogen Idec
  • C.H. Boehringer Sohn AG & Ko. KG
  • Celgene Corporation
  • Dr.Reddy's Laboratories
  • Eli Lilly and Company
  • Forward Pharma
  • Johnson & Johnson Services, Inc.
  • Leo Pharma AS
  • Merck & Co., Inc.
  • Merck and Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Stiefel Laboratories Inc.
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • UCB SA

제17장 부록

  • 디스커션 가이드
  • 라이선스와 가격
LSH 21.11.24

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2026 (%)
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2026
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, 2018-2026 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2020 VS 2026 (%)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2020 VS 2026 (USD MILLION)
  • FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2026
  • FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2026
  • FIGURE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
  • FIGURE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
  • FIGURE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (%)
  • FIGURE 38. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2026
  • FIGURE 40. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 41. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 43. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 44. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 46. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
  • FIGURE 47. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2026
  • FIGURE 49. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2026 (USD MILLION)
  • FIGURE 50. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, 2018-2026 (USD MILLION)
  • FIGURE 52. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 53. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, 2018-2026 (USD MILLION)
  • FIGURE 54. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 55. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, 2018-2026 (USD MILLION)
  • FIGURE 56. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 57. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, 2018-2026 (USD MILLION)
  • FIGURE 58. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 59. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, 2018-2026 (USD MILLION)
  • FIGURE 60. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, 2018-2026 (USD MILLION)
  • FIGURE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 63. AMERICAS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 64. ARGENTINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 65. BRAZIL PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 66. CANADA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 67. MEXICO PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 68. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 69. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 70. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 71. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 72. INDIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 73. INDONESIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 74. JAPAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 75. MALAYSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 76. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 77. SINGAPORE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 78. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 79. TAIWAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 80. THAILAND PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 81. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 82. FRANCE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 83. GERMANY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 84. ITALY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 85. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 86. QATAR PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 87. RUSSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 88. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 89. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 90. SPAIN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 91. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 92. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 93. GLOBAL PSORIASIS DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 94. GLOBAL PSORIASIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 95. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PSORIASIS DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2026 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 30. AMERICAS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. ARGENTINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. BRAZIL PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. CANADA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. MEXICO PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. INDIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. INDONESIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. JAPAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. MALAYSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. SINGAPORE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. TAIWAN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. THAILAND PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 49. FRANCE PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 50. GERMANY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 51. ITALY PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 52. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 53. QATAR PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 54. RUSSIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 55. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 56. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 57. SPAIN PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 58. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 59. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS DRUGS MARKET: SCORES
  • TABLE 61. GLOBAL PSORIASIS DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 62. GLOBAL PSORIASIS DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 63. GLOBAL PSORIASIS DRUGS MARKET: RANKING
  • TABLE 64. GLOBAL PSORIASIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 65. GLOBAL PSORIASIS DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 66. GLOBAL PSORIASIS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 67. GLOBAL PSORIASIS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 68. GLOBAL PSORIASIS DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 69. GLOBAL PSORIASIS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 70. GLOBAL PSORIASIS DRUGS MARKET: LICENSE & PRICING

The Global Psoriasis Drugs Market size was estimated at USD 6,932.78 million in 2020 and expected to reach USD 7,732.83 million in 2021, at a CAGR 11.87% to reach USD 13,595.20 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Psoriasis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Therapeutic Class, the market was studied across Interleukin Inhibitors and Tumor Necrosis Factor Inhibitor.
  • Based on Type of Treatment, the market was studied across Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies.
  • Based on Mechanism of Action, the market was studied across Interleukin Inhibitors, PDE4 Inhibitors, and TNF Alpha Inhibitors.
  • Based on Route of Administration, the market was studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Application, the market was studied across Arthritis, Erythrodermic, Guttate, Intertriginous, Nail, Plaque, and Pustular.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Psoriasis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Psoriasis Drugs Market, including AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bausch Health Companies Inc., Biogen Idec, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Dr.Reddy's Laboratories, Eli Lilly and Company, Forward Pharma, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Merck and Co. Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, and UCB SA.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Psoriasis Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Psoriasis Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Psoriasis Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Psoriasis Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Psoriasis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Define: Research Objective
  • 2.3. Determine: Research Design
  • 2.4. Prepare: Research Instrument
  • 2.5. Collect: Data Source
  • 2.6. Analyze: Data Interpretation
  • 2.7. Formulate: Data Verification
  • 2.8. Publish: Research Report
  • 2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of psoriasis
      • 5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
      • 5.1.1.3. Ease of process of approval of psoriasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing awareness regarding treatment and rising demand for improved healthcare infrastructure
      • 5.1.3.2. Adoption of technologically advanced non-invasive or minimally invasive psoriasis treatment procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of the medication
  • 5.2. Cumulative Impact of COVID-19

6. Psoriasis Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Interleukin Inhibitors
  • 6.3. Tumor Necrosis Factor Inhibitor

7. Psoriasis Drugs Market, by Type of Treatment

  • 7.1. Introduction
  • 7.2. Biologic Drugs
  • 7.3. Small Molecule Systemic Drugs
  • 7.4. Tropical Therapies

8. Psoriasis Drugs Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Interleukin Inhibitors
  • 8.3. PDE4 Inhibitors
  • 8.4. TNF Alpha Inhibitors

9. Psoriasis Drugs Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Psoriasis Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Psoriasis Drugs Market, by Application

  • 11.1. Introduction
  • 11.2. Arthritis
  • 11.3. Erythrodermic
  • 11.4. Guttate
  • 11.5. Intertriginous
  • 11.6. Nail
  • 11.7. Plaque
  • 11.8. Pustular

12. Americas Psoriasis Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Psoriasis Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand

14. Europe, Middle East & Africa Psoriasis Drugs Market

  • 14.1. Introduction
  • 14.2. France
  • 14.3. Germany
  • 14.4. Italy
  • 14.5. Netherlands
  • 14.6. Qatar
  • 14.7. Russia
  • 14.8. Saudi Arabia
  • 14.9. South Africa
  • 14.10. Spain
  • 14.11. United Arab Emirates
  • 14.12. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
    • 15.1.1. Quadrants
    • 15.1.2. Business Strategy
    • 15.1.3. Product Satisfaction
  • 15.2. Market Ranking Analysis
  • 15.3. Market Share Analysis, By Key Player
  • 15.4. Competitive Scenario
    • 15.4.1. Merger & Acquisition
    • 15.4.2. Agreement, Collaboration, & Partnership
    • 15.4.3. New Product Launch & Enhancement
    • 15.4.4. Investment & Funding
    • 15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. AstraZeneca PLC
  • 16.4. Bausch Health Companies Inc.
  • 16.5. Biogen Idec
  • 16.6. C.H. Boehringer Sohn AG & Ko. KG
  • 16.7. Celgene Corporation
  • 16.8. Dr.Reddy's Laboratories
  • 16.9. Eli Lilly and Company
  • 16.10. Forward Pharma
  • 16.11. Johnson & Johnson Services, Inc.
  • 16.12. Leo Pharma AS
  • 16.13. Merck & Co., Inc.
  • 16.14. Merck and Co. Inc.
  • 16.15. Novartis International AG
  • 16.16. Pfizer Inc.
  • 16.17. Stiefel Laboratories Inc.
  • 16.18. Sun Pharmaceutical Industries Ltd
  • 16.19. Takeda Pharmaceutical Company Limited
  • 16.20. UCB SA

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing
Back to Top
전화 문의
F A Q